Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA2 | P00918 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096665 | 1.00 | TDP1 (0.55) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL7097924 | 0.92 | TDP1 (0.65) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL1557954 | 0.92 | TDP1 (0.56) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL10030615 | 0.91 | TDP1 (0.61) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL146037 | 0.87 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL368074 | 0.87 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL1286925 | 0.87 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL964035 | 0.87 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL989107 | 0.87 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5866373 | 0.87 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | WOODLE MARTIN C (US) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166601-A1 | Novel colloid synthetic vectors for gene therapy | FUS, HNRNPUL2, HNRNPH1 | TDP1 2446/4885MAOA 4690/4885MAOB 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.